diagnosis
The diagnosis is based on clinical examination, radiological investigations (bilateral mammography and ultrasound; in particular cases MRI or other imaging techniques may be of value) and pathomorphological assessment. Pathologic diagnosis with fine needle aspiration (limited to cases with small nodules or suspicious areas) or core needle biopsy should be obtained before any surgical procedure. Final pathological diagnosis should be made according to the World Health Organization classification and the tumor-node-metastasis (TNM) (International Union Against Cancer and American Joint Comittee Cancer, sixth edition 2002) staging system analyzing all tissue removed.
staging and risk assessment
In case of preoperative systemic treatment a full clinical staging should be carried out at the outset. In case of primary surgery pathologic TNM staging based on hematoxylin and esoin staining, description of histologic type, standardized grading and evaluation of resection margins should be reported. Determination of estrogen receptor (ER) and progesterone receptor (PgR) status is mandatory, preferably by immunohistochemistry [III, B] . Reports of immunohistochemical results for ER and PgR should include the percentage of ER-and PgR-positive cells.According to the St Gallen Consensus hormone receptors are no longer included among the prognostic factors, but are the most relevant predictive factor for the choice of treatment.
Immunohistochemical determination of HER2 receptor expression should be performed at the same time for treatment planning. When semi-quantitative results of immunohistochemistry are ambiguous (++), in situ hybridization (FISH or CISH) to determine HER2 gene amplification should be performed. It is possible to directly perform a gene amplification study (FISH or CISH) and not perform the HER2 immunohistochemistry at all.
Routine staging examinations include physical examination, full blood counts, routine chemistry including liver enzymes, alkaline phosphatase, calcium and assessment of menopausal status. This staging is needed for all patients and it can be acceptable for patients with small clinical tumors (T1) and without palpable nodes. For all other cases and in particular for candidates for pre-operative treatment the conduct of additional investigations should be considered before rather that after surgery.
In patients with higher risk (pathological N2 with four or more positive axillary nodes, or T4 tumors, or with laboratory signs or clinical signs or symptoms suspicious for the presence of metastases), chest X-ray, abdominal ultrasound and isotopic bone scan are appropriate [III, B] .
Treatment decisions are based primarily on endocrine responsiveness of the tumor and secondarily on risk of recurrence. Risk stratification has been revised and currently includes three risk groups: low, intermediate and high risk (Table 1) .Vascular invasion has been described as an important prognostic factor, particularly in node-negative disease.
treatment plan
The multidisciplinary discussion (possibly involving also a pathologist) leading to treatment planning should be used to integrate local and systemic therapies as well as their sequence [III, B] .
The possibility of hereditary cancer should be explored and adequate counseling of relatives evaluated [IV, D] .
local therapy invasive carcinoma
Generally, operable breast cancer is treated initially by surgery, using breast-conserving surgery or mastectomy, both in combination with axillary dissection or a sentinel node biopsy. Contraindications to breast-conserving surgery include multicentric tumors, large tumors (>3-4 cm) in small breasts, possibly retro-areolar localization and tumor-involved margins after resection. Sentinel node biopsy should only be performed in centers with documented experience and accuracy. Sentinel node biopsy should not be performed in case of palpable axillary node(s), T3 or T4 tumors, multicentric tumors, prior axillary surgery or large biopsies, after breast reconstruction or implantation of a prosthesis, during pregnancy or lactation, and after neoadjuvant systemic treatment outside of clinical trials. Breast radiotherapy is strongly recommended after breast-conserving surgery [ 
adjuvant systemic therapy
Treatment decisions are based on two main factors: (i) estimated endocrine responsiveness of tumor tissue and (ii) risk of relapse (Table 1) In premenopausal patients the combination of ovarian function ablation with tamoxifen, or tamoxifen alone (20 mg/ day for 5 years) is indicated. Bilateral ovarectomy or irradiation of the ovaries leads to irreversible ablation of ovarian function. Gonadotropin-releasing hormone analogs (GnRHAs) (e.g. goserelin 3.6 mg s.c. monthly) generally lead to reversible ovarian suppression. They should be given for at least 2 years, but optimal duration for this treatment has not yet been established [III, D] . The adjuvant use of the combination of GnRHA and aromatase inhibitors in premenopausal patients is not currently indicated. The use of aromatase inhibitors alone must be avoided, as no evidence of efficacy is available.
In postmenopausal patients adjuvant endocrine therapy should include an aromatase inhibitor at some point in time. It is as yet undetermined whether aromatase inhibitors should be used upfront, and for which exact time period. Alternatively, tamoxifen is still an option, with a planned switch to an aromatase inhibitor after 2-3 or after 5 years. Adjuvant aromatase inhibitors increase disease-free survival when compared with tamoxifen. This has been shown for anastrozole (1 mg daily for 5 years) and for letrozole (2.5 mg daily for 5 years) given upfront [I, A], for exemestane (25 mg daily) and for anastrozole (1 mg daily) given after 2-3 years of tamoxifen [I, A] and for letrozole (2.5 mg daily) and anastrozole compared with placebo given after 5 years of tamoxifen [I, A]. The long-term cardiovascular and skeletal adverse effects associated with aromatase inhibitors are an issue of concern. Women treated with aromatase inhibitors should receive vitamin D and calcium supplements, while there is no clear evidence for the use of bisphosphonates in the adjuvant setting comcomitantly with aromatase inhibitor. (Tables 1-3) should use a combination regimen (Table 4) . In early 2006 the consensus is that such a combination should include an anthracycline, and should involve a duration of at least four cycles of treatment. The use of taxanes may be limited to high-risk patients, especially if ER-negative where data show a substantial benefit. Controversial is the use of dose-dense schedules with prophylactic G-CSF.
trastuzumab
Patients with HER2 overexpression (3+) or HER2 amplification can benefit from adjuvant treatment with trastuzumab. There is no evidence for the use of trastuzumab in patients with nodenegative, HER2/neu-positive small (<1 cm) tumors, as in this group of patients side-effects may override possible benefits. Based on pharmacokinetic analyses a 3-weekly schedule (6 mg/ kg) is considered equivalent to a weekly schedule (2 mg/kg). The standard duration of adjuvant trastuzumab has not yet been established, For the time being 1 year is recommended. Trastuzumab may be started in parallel with a taxane, but it should not be given concurrently with an anthracycline. Even when given after an anthracycline-containing regimen trastuzumab has cardiotoxic effects and heart function should be routinely monitored.
follow-up
History taking, eliciting of symptoms and physical examination every 3-6 months for 3 years, every 6-12 months for 3 years, then annually [A], with attention being paid to long-term sideeffects, e.g. osteoporosis.
Ipsilateral (after breast-conserving surgery) and contralateral mammography every 1-2 years [D] .
Not routinely recommended for asymptomatic patients: blood counts, chemistry, chest X-ray, bone scan, liver ultrasound, CT scans of chest and abdomen and any tumor markers such as CA 15-3 or CEA [I, A]. 
